Corbus Working Capital vs Accounts Payable Analysis

CRBP Stock

USD 41.12 1.60 3.75%

Corbus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corbus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corbus Pharmaceuticals is a good investment. Please check the relationship between Corbus Pharmaceuticals Working Capital and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Working Capital vs Accounts Payable

Working Capital vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corbus Pharmaceuticals Working Capital account and Accounts Payable. At this time, the significance of the direction appears to have no relationship.

The correlation between Corbus Pharmaceuticals' Working Capital and Accounts Payable is 0.0. Overlapping area represents the amount of variation of Working Capital that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Corbus Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Corbus Pharmaceuticals' Working Capital and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Working Capital of Corbus Pharmaceuticals Holding are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Working Capital i.e., Corbus Pharmaceuticals' Working Capital and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Working Capital

The difference between a company’s current assets and current liabilities, indicating the liquidity and operational efficiency of the business.

Accounts Payable

An accounting item on the balance sheet that represents Corbus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Corbus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Corbus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

At this time, Corbus Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 04/17/2024, Sales General And Administrative To Revenue is likely to grow to 21.89, while Issuance Of Capital Stock is likely to drop slightly above 231.9 K.

Corbus Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other
Common Stock Shares Outstanding		-0.17	0.11	-0.2	-0.16	-0.19	-0.1	0.41	-0.04	-0.34	-0.34	-0.04	-0.16	-0.17	0.08	-0.28	0.03	-0.07	-0.18	0.1	-0.3	-0.31	-0.07	-0.1	-0.08	-0.05
Total Assets	-0.17		0.77	0.2	0.64	0.84	0.67	-0.44	-0.69	0.52	0.76	0.69	0.98	0.77	0.82	0.63	0.8	0.82	1.0	0.21	0.76	0.18	0.87	0.78	0.79	0.53
Short Long Term Debt Total	0.11	0.77		0.16	0.67	0.47	0.76	0.06	-0.88	0.31	0.39	0.75	0.73	0.82	0.89	0.41	0.95	0.88	0.75	0.48	0.41	-0.31	0.67	0.77	0.8	0.73
Other Current Liab	-0.2	0.2	0.16		0.72	-0.09	0.56	-0.15	-0.38	0.8	0.22	0.6	0.11	0.4	0.01	0.79	0.35	0.49	0.15	0.28	0.08	0.2	0.01	0.6	0.57	0.32
Total Current Liabilities	-0.16	0.64	0.67	0.72		0.23	0.89	-0.3	-0.74	0.85	0.59	0.86	0.54	0.77	0.51	0.88	0.76	0.92	0.6	0.46	0.46	0.03	0.45	0.88	0.89	0.73
Total Stockholder Equity	-0.19	0.84	0.47	-0.09	0.23		0.28	-0.55	-0.27	0.2	0.7	0.25	0.92	0.38	0.65	0.33	0.49	0.44	0.86	-0.22	0.79	0.39	0.81	0.41	0.41	0.05
Current Deferred Revenue	-0.1	0.67	0.76	0.56	0.89	0.28		-0.24	-0.67	0.77	0.56	0.75	0.58	0.67	0.72	0.81	0.72	0.94	0.62	0.28	0.49	-0.26	0.36	0.96	0.96	0.69
Net Debt	0.41	-0.44	0.06	-0.15	-0.3	-0.55	-0.24		-0.14	-0.54	-0.89	-0.06	-0.47	-0.07	-0.13	-0.5	-0.01	-0.24	-0.45	0.39	-0.56	-0.64	-0.34	-0.24	-0.23	-0.05
Retained Earnings	-0.04	-0.69	-0.88	-0.38	-0.74	-0.27	-0.67	-0.14		-0.39	-0.3	-0.88	-0.59	-0.96	-0.64	-0.49	-0.94	-0.82	-0.67	-0.78	-0.2	0.16	-0.65	-0.72	-0.75	-0.86
Accounts Payable	-0.34	0.52	0.31	0.8	0.85	0.2	0.77	-0.54	-0.39		0.65	0.68	0.42	0.5	0.32	0.94	0.4	0.72	0.48	0.1	0.48	0.25	0.19	0.8	0.78	0.47
Cash	-0.34	0.76	0.39	0.22	0.59	0.7	0.56	-0.89	-0.3	0.65		0.42	0.76	0.47	0.51	0.66	0.44	0.63	0.77	-0.09	0.69	0.46	0.62	0.58	0.58	0.42
Long Term Debt	-0.04	0.69	0.75	0.6	0.86	0.25	0.75	-0.06	-0.88	0.68	0.42		0.57	0.86	0.59	0.69	0.84	0.88	0.65	0.6	0.33	0.07	0.51	0.83	0.84	0.76
Cash And Short Term Investments	-0.16	0.98	0.73	0.11	0.54	0.92	0.58	-0.47	-0.59	0.42	0.76	0.57		0.67	0.82	0.54	0.76	0.75	0.98	0.06	0.8	0.24	0.88	0.69	0.7	0.4
Common Stock Total Equity	-0.17	0.77	0.82	0.4	0.77	0.38	0.67	-0.07	-0.96	0.5	0.47	0.86	0.67		0.6	0.58	0.91	0.83	0.75	0.73	0.34	0.0	0.72	0.72	0.74	0.86
Non Current Liabilities Total	0.08	0.82	0.89	0.01	0.51	0.65	0.72	-0.13	-0.64	0.32	0.51	0.59	0.82	0.6		0.37	0.77	0.81	0.8	0.08	0.58	-0.24	0.6	0.76	0.78	0.51
Other Current Assets	-0.28	0.63	0.41	0.79	0.88	0.33	0.81	-0.5	-0.49	0.94	0.66	0.69	0.54	0.58	0.37		0.52	0.77	0.59	0.21	0.57	0.19	0.4	0.86	0.84	0.46
Other Stockholder Equity	0.03	0.8	0.95	0.35	0.76	0.49	0.72	-0.01	-0.94	0.4	0.44	0.84	0.76	0.91	0.77	0.52		0.88	0.78	0.57	0.39	-0.07	0.75	0.76	0.79	0.75
Total Liab	-0.07	0.82	0.88	0.49	0.92	0.44	0.94	-0.24	-0.82	0.72	0.63	0.88	0.75	0.83	0.81	0.77	0.88		0.78	0.4	0.56	-0.1	0.59	0.95	0.97	0.76
Total Current Assets	-0.18	1.0	0.75	0.15	0.6	0.86	0.62	-0.45	-0.67	0.48	0.77	0.65	0.98	0.75	0.8	0.59	0.78	0.78		0.19	0.76	0.21	0.89	0.73	0.75	0.5
Short Term Debt	0.1	0.21	0.48	0.28	0.46	-0.22	0.28	0.39	-0.78	0.1	-0.09	0.6	0.06	0.73	0.08	0.21	0.57	0.4	0.19		-0.23	-0.21	0.36	0.28	0.31	0.74
Common Stock	-0.3	0.76	0.41	0.08	0.46	0.79	0.49	-0.56	-0.2	0.48	0.69	0.33	0.8	0.34	0.58	0.57	0.39	0.56	0.76	-0.23		0.22	0.59	0.58	0.57	0.05
Other Liab	-0.31	0.18	-0.31	0.2	0.03	0.39	-0.26	-0.64	0.16	0.25	0.46	0.07	0.24	0.0	-0.24	0.19	-0.07	-0.1	0.21	-0.21	0.22		0.29	-0.12	-0.14	-0.19
Net Tangible Assets	-0.07	0.87	0.67	0.01	0.45	0.81	0.36	-0.34	-0.65	0.19	0.62	0.51	0.88	0.72	0.6	0.4	0.75	0.59	0.89	0.36	0.59	0.29		0.47	0.5	0.44
Property Plant And Equipment Net	-0.1	0.78	0.77	0.6	0.88	0.41	0.96	-0.24	-0.72	0.8	0.58	0.83	0.69	0.72	0.76	0.86	0.76	0.95	0.73	0.28	0.58	-0.12	0.47		1.0	0.63
Non Current Assets Total	-0.08	0.79	0.8	0.57	0.89	0.41	0.96	-0.23	-0.75	0.78	0.58	0.84	0.7	0.74	0.78	0.84	0.79	0.97	0.75	0.31	0.57	-0.14	0.5	1.0		0.66
Non Currrent Assets Other	-0.05	0.53	0.73	0.32	0.73	0.05	0.69	-0.05	-0.86	0.47	0.42	0.76	0.4	0.86	0.51	0.46	0.75	0.76	0.5	0.74	0.05	-0.19	0.44	0.63	0.66

Click cells to compare fundamentals

Corbus Pharmaceuticals Account Relationship Matchups

Corbus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	2.1M	2.6M	4.1M	4.2M	4.3M	2.9M
Total Assets	49.1M	102.3M	107.7M	66.3M	28.3M	50.5M
Short Long Term Debt Total	9.4M	26.8M	26.6M	25.1M	20.9M	11.1M
Other Current Liab	22.4M	797K	133.7K	6.0M	11.1M	5.9M
Total Current Liabilities	34.9M	31.9M	17.0M	12.6M	31.9M	16.9M
Total Stockholder Equity	6.2M	45.3M	69.1M	33.0M	(6.9M)	(6.6M)
Net Debt	(22.3M)	(58.6M)	1.6M	8.1M	7.0M	7.3M
Retained Earnings	(192.8M)	(304.1M)	(349.7M)	(392.1M)	(436.7M)	(414.8M)
Accounts Payable	11.1M	7.4M	1.8M	2.2M	3.2M	4.0M
Cash	31.7M	85.4M	25.0M	17.0M	13.9M	13.2M
Cash And Short Term Investments	31.7M	85.4M	97.6M	59.2M	21.1M	20.0M
Common Stock Total Equity	5.6K	5.7K	6.5K	9.9K	11.4K	11.9K
Liabilities And Stockholders Equity	49.1M	102.3M	107.7M	66.3M	28.3M	50.5M
Non Current Liabilities Total	8.1M	25.1M	21.6M	20.7M	3.3M	3.1M
Other Current Assets	6.4M	3.7M	2.4M	791.6K	2.4M	2.3M
Other Stockholder Equity	199.0M	349.4M	418.9M	425.2M	429.8M	216.4M
Total Liab	43.0M	57.0M	38.6M	33.3M	35.2M	25.1M
Total Current Assets	38.2M	92.1M	100.2M	60.2M	23.5M	46.1M
Short Term Debt	1.3M	1.7M	5.0M	4.4M	17.6M	18.5M
Common Stock	6.5K	9.9K	12.5K	417.0	442.0	419.9
Net Tangible Assets	6.2M	45.3M	69.1M	33.0M	37.9M	32.1M
Property Plant And Equipment Net	10.9M	9.3M	7.0M	5.5M	4.0M	4.6M
Non Current Assets Total	11.0M	10.2M	7.5M	6.1M	4.7M	4.9M
Non Currrent Assets Other	85.0K	234.0K	46.4K	155.3K	212.8K	223.4K
Retained Earnings Total Equity	(65.7M)	(121.4M)	(192.8M)	(304.1M)	(273.7M)	(260.0M)
Capital Surpluse	123.5M	148.9M	199.0M	349.4M	401.8M	421.9M
Property Plant And Equipment Gross	10.9M	9.3M	7.0M	5.5M	7.6M	5.0M
Short Long Term Debt	752.7K	710.2K	3.9M	3.1M	16.2M	17.0M
Accumulated Other Comprehensive Income	(666.6K)	(1.4M)	(62.4K)	(126.1K)	(1.6K)	(1.6K)
Property Plant Equipment	5.1M	9.3M	7.0M	5.5M	6.3M	3.9M

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Corbus Stock

0.77	BIIB	Biogen Inc Earnings Call This Week	Pair Corr
0.76	VRTX	Vertex Pharmaceuticals Financial Report 6th of May 2024	Pair Corr
0.74	AMGN	Amgen Inc Financial Report 25th of April 2024	Pair Corr
0.45	ABVC	ABVC Biopharma	Pair Corr
0.43	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr

The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.

The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock:

How To Invest In Corbus

Details

Is Corbus Stock a good investment?

Details

What is Corbus Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Corbus Stock analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	CEOs Directory Screen CEOs from public companies around the world
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Global Correlations Find global opportunities by holding instruments from different markets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(10.31)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.60)

Return On Equity

(3.42)

The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Corbus Working Capital vs Accounts Payable Analysis

Working Capital vs Accounts Payable

Working Capital vs Accounts Payable Correlation Analysis

Correlation Coefficient

Working Capital

Accounts Payable

Corbus Pharmaceuticals fundamental ratios Correlations

Corbus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Corbus Pharmaceuticals fundamental ratios Accounts

Pair Trading with Corbus Pharmaceuticals

Moving against Corbus Stock

Complementary Tools for Corbus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash And Short Term Investments
Non Current Assets Total	+ 0.97	Total Liab
Property Plant And Equipment Net	+ 0.96	Current Deferred Revenue

Common Stock Total Equity	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Cash	- 0.89	Net Debt
Long Term Debt	- 0.88	Retained Earnings
Retained Earnings	- 0.88	Short Long Term Debt Total
Non Currrent Assets Other	- 0.86	Retained Earnings